FIELD: medicine; oncology.
SUBSTANCE: invention relates to the field of medicine, namely to oncology, and it is intended for the treatment of malignant neoplasm. A method for the treatment of malignant neoplasm in a patient includes the administration of avelumab to the patient according to a dosing mode of 400-800 mg of a fixed dose once every 2 weeks.
EFFECT: use of the invention allows for increasing the efficiency and safety of the treatment of malignant neoplasm.
4 cl, 9 dwg, 6 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED METHODS FOR TREATING WITH PD-L1 ANTAGONISTS | 2016 |
|
RU2766890C2 |
| COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| STABLE FORMULATIONS OF ANTIBODIES TO HUMAN PROGRAMMED DEATH RECEPTOR PD-1 AND RELATED TREATMENT METHODS | 2012 |
|
RU2563346C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
| ANTIBODIES AGAINST EDB AND ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2758632C2 |
| USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS | 2017 |
|
RU2762746C2 |
| COMBINATION OF PD-1 ANTAGONIST AND ERIBULIN FOR TREATING CANCER | 2016 |
|
RU2737216C2 |
